Annual Information Update

RNS Number : 6727J

Oxford Biomedica PLC

01 April 2010

 



For Immediate Release

1 April 2010

Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

Annual Information Update for the Twelve Months to 1 April 2010

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.

1.                   Announcements made via a Regulatory Information Service

Date	Announcement
14 April 2009	Holding(s) in Company
17 April 2009	Holding(s) in Company
29 April 2009	New development collaboration with Sanofi-aventis for ocular diseases
29 April 2009	Termination of development collaboration for TroVax
1 May 2009	Holding(s) in Company
11 May 2009	Update on patent infringement litigation
14 May 2009	Interim management statement
28 May 2009	Blocklisting interim review
29 May 2009	Total voting rights update
1 June 2009	Update on Phase I/II and II TroVax clinical trials
4 June 2009	AGM result
18 June 2009	Corporate presentation at Piper Jaffray Europe conference
18 June 2009	Holding(s) in Company
19 June 2009	Holding(s) in Company (amendment)
6 July 2009	Outcome of FDA review of TroVax
13 July 2009	ProSavin clinical trial update
5 August 2009	Notice of interim results
6 August 2009	Analyst meeting - change of time
7 August 2009	Corporate presentation at Canaccord Adams Global Growth Conference
19 August 2009	Notice that TroVax Phase III data will be presented at ECCO/ESMO conference
27 August 2009	Interim results
28 August 2009	Total voting rights update
1 September 2009	Director's interest in shares
4 September 2009	Corporate presentation at Rodman & Renshaw conference
22 September 2009	TroVax Phase III data presented at ECCO/ESMO conference
30 September 2009	Total voting rights update
15 October 2009	ProSavin clinical trial update
19 October 2009	Holding(s) in Company
30 October 2009	Total voting rights update
19 November 2009	Interim management statement
27 November 2009	Blocklisting interim review
3 December 2009	Holding(s) in Company
15 December 2009	Orphan Drug designation granted for StarGen in Europe
5 January 2010	Management and Board changes
20 January 2010	Orphan Drug designation granted for UshStat in Europe
22 January 2010	Purchase of patent rights and issue of shares
27 January 2010	Settlement of patent litigation with Bavarian Nordic
27 January 2010	Extension of research collaboration in motor neurone disease
29 January 2010	Total voting rights update
17 February 2010	Notice of results
26 February 2010	Total voting rights update
10 March 2010	Preliminary results for 2009
29 March 2010	2009 annual report & accounts and AGM notification
31 March 2010	Total voting rights update
1 April 2010	Annual information update

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk 

2.                  Documents filed with Companies House

Date	Document Type	Description
4 June 2009	AGM Special Business	AGM minutes
18 September 2009	88(2) Return of Allotment of shares	Allotment 1,658,052 1p Ord.
24 September 2009	363a Annual Return	Annual return
7 December 2009	SH01 Return of Allotment of shares	Allotment 28,973 1p Ord.

Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk 

3.                  Documents published or sent to shareholders or filed with the UKLA Viewing Facility

Date	Description
9 September 2009	Interim Report for 6 months to 30 June 2009
29 March 2010	Annual report for the year ended 31 December 2009

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford

OX4 4GA

1 April 2010

 

END

 

 

AIUZFLFBBZFEBBF